TGFB1 and pulmonary arterial hypertension: A recent systematic review ranked the relative strength of evidence supporting different PAH-related mutations, and listed several mutations in the TGF-β signaling pathway in addition to BMPR2 which were classified as having definitive, moderate, limited and disputed evidence for being causal in PAH [3].